The prognostic capacity of B-type natriuretic peptide on cognitive disorder varies by age

References

• Kerola T, Kettunen R, Nieminen T. The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly? Int J Cardiol. 2011;150:123–9.
   PubMed Web of Science ®Google Scholar
• Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol. 2008;585:97–108.
   PubMed Web of Science ®Google Scholar
• Vuolteenaho O, Ala-Kopsala M, Ruskoaho H. BNP as a biomarker in heart disease. Adv Clin Chem. 2005;40:1–36.
   PubMed Web of Science ®Google Scholar
• Buerger K, Ernst A, Ewers M, Uspenskaya O, Omerovic M, Morgenthaler NG, . Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio. Biol Psychiatry. 2009;65:979–84.
   PubMed Web of Science ®Google Scholar
• Kerola T, Nieminen T, Hartikainen S, Sulkava R, Vuolteenaho O, Kettunen R. B-type natriuretic peptide as a predictor of declining cognitive function and dementia—a cohort study of an elderly general population with a 5-year follow-up. Ann Med. 2010;42:207–15.
   PubMed Web of Science ®Google Scholar
• Feola M, Rosso GL, Peano M, Agostini M, Aspromonte N, Carena G, . Correlation between cognitive impairment and prognostic parameters in patients with congestive heart failure. Arch Med Res. 2007;38:234–9.
   PubMed Web of Science ®Google Scholar
• Gunstad J, Poppas A, Smeal S, Paul RH, Tate DF, Jefferson AL, . Relation of brain natriuretic peptide levels to cognitive dysfunction in adults > 55 years of age with cardiovascular disease. American J Cardiol. 2006;98:538–40.
   PubMed Web of Science ®Google Scholar
• Naito J, Naka Y, Watanabe H. Clinical impression of brain natriuretic peptide levels in demented patients without cardiovascular disease. Geriatr Gerontol Int. 2009;9:242–5.
   PubMed Web of Science ®Google Scholar
• Kondziella D, Gothlin M, Fu M, Zetterberg H, Wallin A. B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia. Neuroreport. 2009;20:825–7.
   PubMed Web of Science ®Google Scholar
• Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976–82.
   PubMed Web of Science ®Google Scholar
• Buerger K, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Blennow K, . Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. J Clin Psychiatry. 2011;72:556–63.
   PubMed Web of Science ®Google Scholar
• Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Heid IM, Muders F, . Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens. 2000;18:1121–8.
   PubMed Web of Science ®Google Scholar
• Sayama H, Nakamura Y, Saito N, Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis. 1999;10:537–40.
   PubMed Web of Science ®Google Scholar
• Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009:341–66.
   PubMedGoogle Scholar
• Alehagen U, Svensson E, Dahlstrom U. Natriuretic peptide biomarkers as information indicators in elderly patients with possible heart failure followed over six years: a head-to-head comparison of four cardiac natriuretic peptides. J Card Fail. 2007;13:452–61.
   PubMed Web of Science ®Google Scholar
• Bhandari SS, Davies JE, Struck J, Ng LL. Influence of confounding factors on plasma mid-regional pro-adrenomedullin and mid-regional pro-A-type natriuretic peptide concentrations in healthy individuals. Biomarkers. 2011;16:281–7.
   PubMed Web of Science ®Google Scholar
• Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail. 2003;5:599–606.
   PubMed Web of Science ®Google Scholar
• Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev. 2003;24:341–56.
   PubMed Web of Science ®Google Scholar
• Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther. 2004;102: 223–41.
   PubMed Web of Science ®Google Scholar
• Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, . Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 2002;288:1252–9.
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, . Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9–13.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, . Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988–94.
   PubMed Web of Science ®Google Scholar
• Ala-Kopsala M, Ruskoaho H, Leppaluoto J, Seres L, Skoumal R, Toth M, . Single assay for amino-terminal fragments of cardiac A- and B-type natriuretic peptides. Clin Chem. 2005;51:708–18.
   PubMed Web of Science ®Google Scholar